True Freedom Investing LLC Invests $6.05 Million in AbbVie Inc. $ABBV

True Freedom Investing LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 27,808 shares of the company's stock, valued at approximately $6,048,000. AbbVie comprises about 0.5% of True Freedom Investing LLC's holdings, making the stock its 19th biggest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. LM Advisors LLC acquired a new position in AbbVie during the second quarter worth $300,000. Berry Wealth Group LP bought a new stake in AbbVie during the second quarter worth $222,000. Haverford Trust Co acquired a new stake in AbbVie in the second quarter valued at $20,344,000. Clear Harbor Asset Management LLC acquired a new stake in AbbVie in the second quarter valued at $6,848,000. Finally, First Nebraska Trust Co bought a new position in shares of AbbVie in the 2nd quarter valued at about $1,805,000. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on ABBV. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, August 4th. Wolfe Research upgraded shares of AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 target price for the company in a research note on Thursday, August 13th. BMO Capital Markets lifted their price target on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Canaccord Genuity Group boosted their price target on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Finally, Bank of America upped their price objective on AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $275.95.

AbbVie Price Performance

ABBV stock opened at $261.50 on Thursday. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The stock has a market cap of $462.02 billion, a price-to-earnings ratio of 73.87, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. The company has a fifty day moving average price of $254.23 and a two-hundred day moving average price of $229.67.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie's dividend payout ratio (DPR) is 195.48%.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source